MedTrace Logo

Changes of Muramyl Dipeptide in Intestinal and Extra-intestinal Diseases

NCT04924686 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2021-06-14

No results posted yet for this study

Summary

Nucleotide-binding oligomerization domain 2 (Nod2) signaling is critical for human health.To figure out the clinical relevance of NOD2 ligands, the investigators plan to evaluate the change of NOD2 ligands in inflammatory bowel diseases (IBD), CRC, atherosclerotic cardiovascular disease (ACVD), and type 2 diabetes mellitus (DM2 ).

Conditions

Interventions

OTHER

Observational studies, no intervention

Observational studies, no intervention

Sponsors & Collaborators

  • National Natural Science Foundation of China

    collaborator OTHER_GOV

  • Zhujiang Hospital

    lead OTHER

Principal Investigators

  • Hongwei Zhou, professor · Zhujiang Hospital, Guangzhou, Guangdong

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-10
Primary Completion
2023-06-10
Completion
2023-08-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04924686 on ClinicalTrials.gov